Splicing and gene expression changes in cell lines treated with splicing switching oligonucleotide targeting TRA2B

RNA-sequencing data from MDA-MB231 breast cancer cells, U87MG glioblastoma cells, and mouse breast cancer PDX models treated with antisense oligonucleotides targeting exon 2 of TRA2B. Additionally, RNA-sequencing data from MDA-MB231 breast cancer cells and U87MG glioblastoma cells treated with siRNAs targeting TRA2B. RNA-sequencing data from MDA-MB231 breast cancer cells nad U87MG glioblastoma cells treated with antisense oligonucleotides targeting exon 2 of TRA2B. We examined the differential gene expression and splicing changes in cell lines (MDA-MB231 breast cancer cells and U87MG glioblastoma cells) treated with ASO-1570 (targeting TRA2B) vs a control ASO at different doses (50nM and 200nM). Additionally, we performed similar experiments in breast cancer PDX models treated with ASO-1570 (targeting TRA2B) vs a control ASO at 50mg/kg. Finally, we provide RNA-sequencing data of cell lines (MDA-MB231 breast cancer cells and U87MG glioblastoma cells) treated with siRNAs targeting TRA2B and respective negative controls. We examined the differential gene expression and splicing changes in cell lines treated with 200nM ASO-1570 (targeting tRA2B) vs a 200nM control ASO.

本数据集包含经靶向TRA2B第2外显子的反义寡核苷酸（Antisense Oligonucleotide, ASO）处理的MDA-MB231乳腺癌细胞、U87MG胶质母细胞瘤细胞以及小鼠乳腺癌患者来源的异种移植（Patient-Derived Xenograft, PDX）模型的RNA测序数据。此外，本数据集还包含经靶向TRA2B的小干扰RNA（small interfering RNA, siRNA）处理的MDA-MB231乳腺癌细胞与U87MG胶质母细胞瘤细胞的RNA测序数据。另有经靶向TRA2B第2外显子的反义寡核苷酸处理的MDA-MB231乳腺癌细胞与U87MG胶质母细胞瘤细胞的RNA测序数据。本研究分析了经不同剂量（50nM与200nM）的靶向TRA2B的ASO-1570与对照反义寡核苷酸处理的细胞系（MDA-MB231乳腺癌细胞、U87MG胶质母细胞瘤细胞）中的差异基因表达与可变剪接变化。此外，本研究还在经50mg/kg剂量的靶向TRA2B的ASO-1570与对照反义寡核苷酸处理的乳腺癌PDX模型中开展了类似实验。最后，本数据集提供了经靶向TRA2B的siRNA及其对应阴性对照处理的细胞系（MDA-MB231乳腺癌细胞、U87MG胶质母细胞瘤细胞）的RNA测序数据。本研究还分析了经200nM靶向TRA2B的ASO-1570与200nM对照反义寡核苷酸处理的细胞系中的差异基因表达与可变剪接变化。